Robert Zeldin
Hoofd Techniek/Wetenschap/O&O bij MEIRAGTX HOLDINGS PLC
Vermogen: 422 600 $ op 30-04-2024
Actieve functies van Robert Zeldin
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
MEIRAGTX HOLDINGS PLC | Hoofd Techniek/Wetenschap/O&O | 05-08-2020 | - |
Loopbaan van Robert Zeldin
Eerdere bekende functies van Robert Zeldin
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
ACCELERON PHARMA INC. | Hoofd Techniek/Wetenschap/O&O | 05-07-2018 | 05-04-2019 |
STALLERGENES | Hoofd Techniek/Wetenschap/O&O | 01-01-2011 | 01-01-2015 |
Corporate Officer/Principal | 01-01-2011 | 01-01-2015 | |
IMMUNOVANT, INC. | Hoofd Techniek/Wetenschap/O&O | - | - |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Corporate Officer/Principal | - | - |
Center for Biologics Evaluation & Research
Center for Biologics Evaluation & Research Miscellaneous Commercial ServicesCommercial Services Center for Biologics Evaluation & Research engages in the regulation of biological and related products. Its scope includes blood, vaccines, allergenics, tissues, and cellular and gene therapies. The company is headquartered in Silver Spring, MD. | Hoofd Techniek/Wetenschap/O&O | - | - |
ABLYNX | Hoofd Techniek/Wetenschap/O&O | 01-12-2015 | - |
Opleiding van Robert Zeldin
Tufts University School of Medicine | Doctorate Degree |
The Johns Hopkins University | Undergraduate Degree |
Statistieken
Internationaal
Verenigde Staten | 7 |
Frankrijk | 2 |
België | 2 |
Operationeel
Chief Tech/Sci/R&D Officer | 6 |
Corporate Officer/Principal | 2 |
Doctorate Degree | 1 |
Sectoraal
Health Technology | 7 |
Consumer Services | 3 |
Commercial Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
IMMUNOVANT, INC. | Health Technology |
MEIRAGTX HOLDINGS PLC | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
Stallergenes SA
Stallergenes SA Pharmaceuticals: MajorHealth Technology Stallergenes SA is an international biopharmaceutical company, which engages in the manufacture and sale of pharmaceutical products for the treatment of allergy-related respiratory diseases. The company operates through the Allergen Immunotherapy segment, which provides products and services for the desensitization of allergy-related respiratory conditions. Its products include a range of sublingual route and subcutaneous route products for the treatment of respiratory diseases such as rhino-conjunctivitis, rhinitis, and allergic asthma. Stallergenes was founded in 1962 and is headquartered in Antony, France. | Health Technology |
Ablynx NV
Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium. | Health Technology |
Center for Biologics Evaluation & Research
Center for Biologics Evaluation & Research Miscellaneous Commercial ServicesCommercial Services Center for Biologics Evaluation & Research engages in the regulation of biological and related products. Its scope includes blood, vaccines, allergenics, tissues, and cellular and gene therapies. The company is headquartered in Silver Spring, MD. | Commercial Services |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Acceleron Pharma, Inc.
Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. | Health Technology |
- Beurs
- Insiders
- Robert Zeldin
- Ervaring